1-(3-羟丙基)-4-甲基哌嗪 | 5317-33-9

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-羟丙基)-4-甲基哌嗪
• 中文别名: 1-(3-羟基丙基)-4-甲基哌嗪；1-(3羟丙基)-4-甲基哌嗪
• 英文名称: 3-(4-methyl-1-piperazinyl)-1-propanol
• 英文别名: 3-(4-methylpiperazin-1-yl)propan-1-ol；1-(3-hydroxypropyl)-4-methylpiperazine
• CAS: 5317-33-9
• 化学式: C₈H₁₈N₂O
• mdl: MFCD00009781
• 分子量: 158.244
• InChiKey: JKRSQNBRNIYETC-UHFFFAOYSA-N

物化性质

• 熔点：
  30 °C
• 沸点：
  75-78°C/0.5mm
• 密度：
  0.988±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933599090
• 安全说明：
  S24/25
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  室温

SDS

Name:	3-(N-Methylpiperazine)-Propanol Material Safety Data Sheet
Synonym:	None known
CAS:	5317-33-9

Section 1 - Chemical Product MSDS Name:3-(N-Methylpiperazine)-Propanol Material Safety Data Sheet
Synonym:None known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
5317-33-9	3-(N-Methylpiperazino)-Propanol	ca 100	226-177-6

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Corrosive.
Potential Health Effects
Eye:
Causes eye burns. May cause chemical conjunctivitis and corneal damage.
Skin:
Causes skin burns. May cause skin rash (in milder cases), and cold and clammy skin with cyanosis or pale color.
Ingestion:
May cause severe and permanent damage to the digestive tract. Causes gastrointestinal tract burns. May cause perforation of the digestive tract. May cause systemic effects.
Inhalation:
Causes chemical burns to the respiratory tract. Aspiration may lead to pulmonary edema. May cause systemic effects. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed. Extensive irrigation with water is required (at least 30 minutes).
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Destroy contaminated shoes.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water spray to keep fire-exposed containers cool. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Contact with metals may evolve flammable hydrogen gas. Containers may explode when heated. Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes.
Extinguishing Media:
Do NOT get water inside containers. For small fires, use dry chemical, carbon dioxide, or water spray. For large fires, use dry chemical, carbon dioxide, alcohol-resistant foam, or water spray.
Cool containers with flooding quantities of water until well after fire is out.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Avoid runoff into storm sewers and ditches which lead to waterways.
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Absorb spill using an absorbent, non-combustible material such as earth, sand, or vermiculite. Do not use combustible materials such as sawdust.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use only in a well-ventilated area.
Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Discard contaminated shoes.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 5317-33-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless, oily
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 120-121C @ 9mm Hg
Freezing/Melting Point: < 20 deg C
Autoignition Temperature: Not applicable.
Flash Point: > 109 deg C (> 228.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H18N2O
Molecular Weight: 158.1388

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, acid chlorides, acid anhydrides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 5317-33-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(N-Methylpiperazino)-Propanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Products which are considered hazardous for supply are classified as Special Waste and the disposal of such chemicals is covered by regulations which may vary according to location. Contact a specialist disposal company or the local waste regulator for advice. Empty containers must be decontaminated before returning for recycling.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 5317-33-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 5317-33-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 5317-33-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(3-羟丙基)-4-甲基哌嗪 在 palladium on activated charcoal 氢气 、 sodium 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 7.0h， 生成 N-[4-[(3-methylphenyl)amino]-7-[3-N-(4-methylpiperazinyl)-propyloxy]-quinazolin-6-yl]-acrylamide
  参考文献：
  名称：

  酪氨酸激酶抑制剂。17.表皮生长因子受体的不可逆抑制剂：具有附加增溶功能的4-（苯基氨基）喹唑啉-和4-（苯基氨基）吡啶并[3，2-d]嘧啶-6-丙烯酰胺。

  摘要：

  通过使相应的6-胺与丙烯酸或丙烯酸酐反应，制备被可溶的7-烷基胺或7-烷氧基胺侧链取代的4-苯胺基喹唑啉-和4-苯胺基吡啶并[3，2-d]嘧啶-6-丙烯酰胺。在吡啶并[3,2-d]嘧啶系列中，中间体7-氨基-6-烷基胺是由7-溴-6-氟吡啶并[3,2-d]嘧啶在适当的条件下，通过钯与适当的锡烷偶联而制得的。 0）催化。这证明了引入阳离子增溶侧链的通用方法。评价化合物对分离的EGFR酶的磷酸化的抑制，以及对A431细胞中EGFR的EGF刺激的EGFR自身磷酸化的抑制以及MDA-MB 453细胞中调蛋白刺激的erbB2自身磷酸化的抑制。具有7-烷氧基胺增溶基团的喹唑啉类似物是分离的EGFR酶的有效不可逆抑制剂，IC（50p）值为2至4nM，并有效抑制细胞中的EGFR和erbB2自磷酸化。7-烷基氨基-和7-烷氧基氨基吡啶并[3,2-d]嘧啶也是不可逆的抑制剂，对分离的酶具有相同或更高的效力，但

  DOI：

  10.1021/jm990482t
• 作为产物：
  描述：

  N-甲基哌嗪 在 乙醇 、 sodium 作用下， 生成 1-(3-羟丙基)-4-甲基哌嗪
  参考文献：
  名称：

  Ratouis; Combes, Bulletin de la Societe Chimique de France, 1959, p. 576,578

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-[(2,4-二氯-5-甲氧基苯基)氨基]-7-氟-6-甲氧基-3-喹啉甲腈 、 1-(3-羟丙基)-4-甲基哌嗪 在 1-(3-羟丙基)-4-甲基哌嗪 作用下， 以55的产率得到博舒替尼一水化合物
  参考文献：
  名称：

  [EN] 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY
  [FR] 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALCOXY-3-QUINOLINECARBONITRILES POUR LE TRAITEMENT DES LESIONS ISCHEMIQUES

  摘要：

  公式（I）的化合物，其中X为N，CHn为1-3的整数；R'和R分别独立地表示1到3个碳原子的烷基，以及其药学上可接受的盐，但当n为1时，X不是N。这些化合物可用于抑制疾病、损伤或其他创伤引起的血管通透性。

  公开号：

  WO2004075898A1

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• [EN] NOVEL PYRROLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRROLE
  申请人：UNIV LEICESTER

  公开号：WO2014195705A1

  公开（公告）日：2014-12-11

  There are provided inter alia compounds of formula (I), wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.

  其中提供了式（I）的化合物，其中R1、R2、R3、R4a和R4b如规范中定义，并且它们在治疗中的用途，特别是在细菌感染（例如肺炎球菌感染）的治疗中。
• 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
  申请人：Aurrecoechea Natalia

  公开号：US20100081653A1

  公开（公告）日：2010-04-01

  2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.

  2-[1H-苯并咪唑-2(3H)-基]-2-(嘧啶-2-基)乙酰胺和2-[苯并噻唑-2(3H)-基]-2-(嘧啶-2-基)乙酰胺及其盐是激酶抑制剂，在癌症治疗中有用。
• Manganese-Catalyzed Anti-Markovnikov Hydroamination of Allyl Alcohols via Hydrogen-Borrowing Catalysis
  作者：Kuhali Das、Koushik Sarkar、Biplab Maji

  DOI：10.1021/acscatal.1c01199

  日期：2021.6.18

  In this article, a selective formal anti-Markovnikov hydroamination of allyl alcohols is presented. It enables the versatile synthesis of valuable γ-amino alcohol building blocks. A phosphine-free Earth’s abundant manganese(I) complex catalyzed the reaction under hydrogen-borrowing conditions. A vast range of aliphatic, aromatic amines, drug molecules, and natural product derivatives underwent successful

  控制加氢胺化反应的选择性对于胺的多样化来说是一项极具挑战性但非常理想的任务。在本文中，介绍了烯丙醇的选择性正式反马尔科夫尼科夫加氢胺化。它使有价值的 γ-氨基醇构建块的多功能合成成为可能。一种不含磷的地球上丰富的锰 (I) 配合物在借氢条件下催化了该反应。大量的脂肪族、芳香族胺、药物分子和天然产物衍生物与具有优异官能团耐受性的伯烯和仲烯丙醇成功加氢胺化（57 个例子）。该催化可以在克级进行，并已应用于药物分子的合成。
• Derivatives of Amphotericin B
  申请人：Revolution Medicines, Inc.

  公开号：US20160304548A1

  公开（公告）日：2016-10-20

  Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3′-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2′epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.

  披露了与AmB相比具有改善的治疗指数的Amphotericin B（AmB）衍生物。这些AmB衍生物包括根据公式（I）的C16脲、碳酸酯和酰胺；根据公式（II）的C3′-取代的C16脲、碳酸酯和酰胺；根据公式（III）的C16酰基；根据公式（IV）的C2′epi-C16脲、碳酸酯和酰胺；以及根据公式（V）的C16噁唑烷酮衍生物。还披露了包括这些AmB衍生物的药物组合物，以及使用这些AmB衍生物的治疗方法。

表征谱图